Griffiths, RR; Richards, WA; McCann, U; Jesse, R. Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance. Psychopharmacology, 1 Aug 2006, 187 (3), 268–283. 342 kB. https://doi.org/10.1007/s00213-006-0457-5
Clarke, EGC. The identification of amphetamine type drugs. J. Forensic Sci. Soc., 1 Jan 1967, 7 (1), 31–36. 770 kB. https://doi.org/10.1016/S0015-7368(67)70368-0
McLaughlin, G; Morris, N; Kavanagh, PV; Power, JD; Dowling, G; Twamley, B; O’Brien, J; Hessman, G; Murphy, B; Walther, D; Partilla, JS; Baumann, MH; Brandt, SD. Analytical characterization and pharmacological evaluation of the new psychoactive substance 4-fluoromethylphenidate (4F-MPH) and differentiation between the (±)-threo- and (±)-erythro- diastereomers. Drug Test. Analysis, 1 Mar 2017, 9 (3), 347-357. 1.9 MB. https://doi.org/10.1002/dta.2167
Markowitz, JS; Zhu, H; Patrick, KS. Isopropylphenidate: An Ester Homolog of Methylphenidate with Sustained and Selective Dopaminergic Activity and Reduced Drug Interaction Liability. J. Child Adol. Psychop., 18 Dec 2013, 23 (10), 648–654. 328 kB. https://doi.org/10.1089/cap.2013.0074
Luethi, D; Kaeser, PJ; Brandt, SD; Krähenbühl, S; Hoener, MC; Liechti, ME. Pharmacological profile of methylphenidate-based designer drugs. Neuropharmacology, 18 Aug 2017, n/a. 987 kB. https://doi.org/10.1016/j.neuropharm.2017.08.020
Grafinger, KE; Hädener, M; König, S; Weinmann, W. Study of the in vitro and in vivo metabolism of the tryptamine 5-MeO-MiPT using human liver microsomes and real case samples. Drug Test. Analysis, 1 Mar 2018, 10 (3), 562-574. 1.2 MB. https://doi.org/10.1002/dta.2245
Barrett, FS; Griffiths, RR. Classic hallucinogens and mystical experiences: Phenomenology and neural correlates. In Behavioral Neurobiology of Psychedelic Drugs; Halberstadt, AL; Vollenweider, FX; Nichols, DE, Eds., Springer, 1 Jan 2017; pp 137-158. 848 kB. https://doi.org/10.1007/7854_2017_474
Montenarh, D; Hopf, M; Warth, S; Maurer, HH; Schmidt, P; Ewald, AH. A simple extraction and LC-MS/MS approach for the screening and identification of over 100 analytes in eight different matrices: Detection of 130 analytes in eight biosamples using only one LC-MS/MS method. Drug Test. Analysis, 1 Mar 2015, 7 (3), 214-240. 593 kB. https://doi.org/10.1002/dta.1657
Calderon, SN; Klein, M. A regulatory perspective on the abuse potential evaluation of novel stimulant drugs in the United States. Neuropharmacology, 1 Dec 2014, 87, 97-103. 266 kB. https://doi.org/10.1016/j.neuropharm.2014.04.001
Wilkins, C; Sweetsur, P. The impact of the prohibition of benzylpiperazine (BZP) ‘legal highs’ on the prevalence of BZP, new legal highs and other drug use in New Zealand. Drug Alcohol Depend., 1 Jan 2013, 127 (1-3), 72-80. 521 kB. https://doi.org/10.1016/j.drugalcdep.2012.06.014
Biel, JH; Bopp, BA. Amphetamines: Structure-activity relationships. In Handbook of Psychopharmacology: Stimulants; Iversen, LL; Iversen, SD; Snyder, SH, Eds., Plenum Press, New York, ; Vol. 11, pp 1–39. 1.0 MB. https://doi.org/10.1007/978-1-4757-0510-2_1
Broadley, KJ. The vascular effects of trace amines and amphetamines. Pharmacol. Ther., 1 Mar 2010, 125 (3), 363–375. 1.1 MB. https://doi.org/10.1016/j.pharmthera.2009.11.005 #methylphenidate
Takahashi, M; Suzuki, J; Nagashima, M; Seto, T; Yasuda, I. Analysis of anesthetics in uncontrolled drugs. Ann. Rep. Tokyo Metr. Inst. P. H., 1 Jan 2005, 56 65–68. 975 kB. #RIT GC,LC,MS,NMR,IR,UV,TLC,other
Nichols, DE. CNS Stimulants. In Burger's Medicinal Chemistry and Drug Discovery; Abraham, DJ, Ed., John Wiley & Sons, Inc., 29 Jan 2010; pp 89–120. 1.8 MB. https://doi.org/10.1002/0471266949.bmc243 #8
Hudkins, RL; Marino, MJ; Williams, M. Cognition. In Burger's Medicinal Chemistry and Drug Discovery; Abraham, DJ, Ed., John Wiley & Sons, Inc., 29 Jan 2010; pp 15–60. 784 kB. https://doi.org/10.1002/0471266949.bmc242 #9
Chambers, SA; DeSousa, JM; Huseman, ED; Townsend, SD. The DARK side of total synthesis: Strategies and tactics in psychoactive drug production. ACS Chem. Neurosci., 17 Oct 2018, 9 (10), 2307–2330. 8.1 MB. https://doi.org/10.1021/acschemneuro.7b00528 #128
Wenthur, CJ. Classics in Chemical Neuroscience: Methylphenidate. ACS Chem. Neurosci., 17 Aug 2016, 7 (8), 1030–1040. 1.7 MB. https://doi.org/10.1021/acschemneuro.6b00199 #1
Luethi, D; Liechti, ME. Monoamine transporter and receptor interaction profiles in vitro predict reported human doses of novel psychoactive stimulants and psychedelics. Int. J. Neuropsychoph., 1 Oct 2018, 21 (10), 926–931. 254 kB. https://doi.org/10.1093/ijnp/pyy047 #S1 Piperidines Methylphenidate
Yadav-Samudrala, BJ; Eltit, JM; Glennon, RA. Synthetic cathinone analogs structurally related to the central stimulant methylphenidate as dopamine reuptake inhibitors. ACS Chem. Neurosci., 1 Aug 2019, n/a. 354 kB. https://doi.org/10.1021/acschemneuro.9b00284 #1 NMR
Bork, W; Dahlenburg, R; Gimbel, M; Jacobsen-Bauer, A; Zörntlein, S. Herleitung Von Grenzwerten Der „nicht Geringen Menge“ Im Sinne Des Btmg. Toxichem Krimtech, 1 Jan 2019, 86 (1), 5–91. 4.4 MB. #PP-004, PP-005, PP-006
Carlier, J; Giorgetti, R; Varì, MR; Pirani, F; Ricci, G; Busardò, FP. Use of cognitive enhancers: methylphenidate and analogs. Eur. Rev. Med. Pharmacol. Sci., 1 Jan 2019, (1), 3–15. 676 kB. https://doi.org/10.26355/eurrev_201901_16741 #MPH